{"product_id":"arcusbio-swot-analysis","title":"Arcus Biosciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eArcus Biosciences shows promising immuno-oncology assets and strategic partnerships but faces clinical, regulatory, and financing risks that could impact valuation; our full SWOT breaks down competitive positioning, pipeline milestones, and potential catalysts. Purchase the complete SWOT analysis to receive a professionally written, editable Word report and Excel matrix—ready for investor decks, due diligence, and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnership with Gilead Sciences\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe long-term collaboration with Gilead Sciences gives Arcus Biosciences $500M+ in committed R\u0026amp;D funding and equity (including a $100M equity investment in 2024), lowering cash burn risk for this clinical-stage biotech; Arcus reported $312M cash and equivalents at 2024 year-end. By tapping Gilead’s global commercial network—sales in 35+ countries—Arcus’ late-stage candidates gain a clear commercial pathway post-approval, reducing go-to-market execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Multi-Modality Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcus holds a diversified pipeline of small molecules and antibodies against TIGIT, adenosine signaling, and HIF-2a, with 7+ active programs as of Dec 31, 2025 and $730M cash pro forma (2025 guidance), enabling multiple combo strategies that match industry trends where 60–70% of late-stage IO trials test combinations. This multi-mechanism slate lowers single-drug failure risk and improves partnering value in licensing talks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Cash Position and Financial Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpas of late arcus biosciences held approximately million in cash and equivalents providing a multi-year runway to fund ongoing phase trials without near-term dilutive financings. this cushion lets management prioritize long-term efficacy safety readouts rather than short-term survival. investors value the reduced refinancing risk volatile biotech market lowering perceived funding-related downside. strong balance sheet supports strategic partnerships trial continuity through\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpertise in Adenosine Pathway Modulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eArcus Biosciences is a recognized leader in targeting the adenosine pathway, a key mediator of immune suppression in the tumor microenvironment, with programs aimed at reversing checkpoint inhibitor resistance.\u003c\/p\u003e\n\u003cp\u003eTheir candidates quemlicostat (AB680) and etrumadenant (AB928) are designed to restore T‑cell activity; as of Dec 31, 2025 Arcus reported 60+ active trials and collaboration revenue of $18.2M in 2025, reinforcing a technical moat versus broader oncology firms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeader in adenosine biology\u003c\/li\u003e\n\u003cli\u003eQuemlicostat, etrumadenant in 60+ trials (2025)\u003c\/li\u003e\n\u003cli\u003e$18.2M collaboration revenue in 2025\u003c\/li\u003e\n\u003cli\u003eFocused moat vs generalist pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Clinical Data for Domvanalimab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDomvanalimab, Arcus’s Fc-silent anti-TIGIT antibody, showed objective response rates ~20–25% in combo NSCLC cohorts and disease control in upper GI cohorts by late-2025, distinguishing its program after competitors’ setbacks.\u003c\/p\u003e\n\u003cp\u003eThe Fc-silent design aims to boost T-cell activity while lowering ADCC-related toxicity; phase 2\/3 safety data reported grade ≥3 AEs below 15%, supporting best-in-class claims.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eORR ~20–25% in NSCLC combos\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 AEs \u0026lt;15%\u003c\/li\u003e\n\u003cli\u003eLate-stage data by 2025 vs competitors\u003c\/li\u003e\n\u003cli\u003eFc-silent design targets efficacy + safety\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcus: $650M cash, $500M+ Gilead support, diversified IO pipeline, clear commercial path\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcus’s strengths: $650M cash (2025 YE) plus $500M+ Gilead commitment incl. $100M equity (2024), diversified IO pipeline (7+ programs, 60+ trials as of Dec 31, 2025), leader in adenosine biology, domvanalimab ORR ~20–25% in NSCLC combos, 2025 collaboration revenue $18.2M—multi-year runway, lower dilution risk, clear commercial path via Gilead.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (2025 YE)\u003c\/td\u003e\n\u003ctd\u003e$650M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead commit\u003c\/td\u003e\n\u003ctd\u003e$500M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms \/ trials\u003c\/td\u003e\n\u003ctd\u003e7+ \/ 60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab rev 2025\u003c\/td\u003e\n\u003ctd\u003e$18.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomvanalimab ORR\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework that highlights Arcus Biosciences’s strengths in immuno-oncology assets and partnerships, weaknesses from clinical and funding risks, opportunities in pipeline expansion and collaborations, and threats from competitive landscape and regulatory\/market uncertainties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT matrix for Arcus Biosciences that speeds strategic alignment and investor-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Gilead Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Gilead partnership provides funding and late-stage heft but creates dependency: Gilead accounted for an estimated 60% of Arcus Biosciences’ collaborative funding in 2024, so Gilead shifts could materially alter Arcus’s cash runway and trial pacing.\u003c\/p\u003e\n\u003cp\u003eIf Gilead reprioritizes oncology or cuts R\u0026amp;D support, Arcus may face delayed INDs and longer time to commercialization; institutional investors flag this concentration as a governance and liquidity risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLack of Commercialized Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of December 31, 2025, Arcus Biosciences remains clinical-stage with no products generating recurring revenue; R\u0026amp;D-stage assets mean zero product sales on the balance sheet.\u003c\/p\u003e\n\u003cp\u003eThe company depended on capital markets and partner milestones, raising $420 million in net proceeds across 2024–2025 and recording $290 million cash burn over that period.\u003c\/p\u003e\n\u003cp\u003eUntil FDA approval and a successful launch, the business model is speculative; failed late-stage readouts could force dilutive financings or asset sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Research and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRunning multiple global Phase 3 trials drives Arcus Biosciences’ R\u0026amp;D spend — $173.6 million in FY 2024 — and costs are rising as the pipeline matures.\u003c\/p\u003e\n\u003cp\u003eThose expenses produced quarterly net losses of $58.2 million in Q3 2025, which can pressure the stock during market risk-off periods.\u003c\/p\u003e\n\u003cp\u003eManaging this cash burn while accelerating timelines demands constant, precise financial oversight to avoid dilution or missed milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Combination Therapy Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eArcus prioritizes combination regimens, which are costlier and more complex than monotherapies; industry median Phase II combination trial costs are ~2–3x higher and Arkus (Arcus) faces similar expense pressure. \u003c\/p\u003e\n\u003cp\u003eProving incremental benefit requires larger cohorts and stricter multiplicity controls; add-on trials often need 300–600 patients versus 100–200 for monotherapy, raising statistical and enrollment burdens.\u003c\/p\u003e\n\u003cp\u003eLonger timelines and higher failure risk follow: combination oncology trials show ~20–30% lower success rates to approval, extending burn and diluting shareholder value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher per-trial cost: ~2–3x monotherapy\u003c\/li\u003e\n\u003cli\u003eNeeded cohort size: ~300–600 vs 100–200\u003c\/li\u003e\n\u003cli\u003eSuccess penalty: ~20–30% lower approval odds\u003c\/li\u003e\n\u003cli\u003eImpacts: longer timelines, higher cash burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Immuno-Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eArcus Biosciences’ narrow immuno-oncology focus raises risk: oncology accounts for 100% of its pipeline and 0% diversification as of 2025, so sector-specific regulatory shifts or reimbursement cuts would hit revenue and valuation hard.\u003c\/p\u003e\n\u003cp\u003eIf the field pivots to cell therapy or gene editing, Arcus’s small-molecule and antibody programs may lose relevance, reducing near-term partnering value and R\u0026amp;D ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100% pipeline concentration in oncology (2025)\u003c\/li\u003e\n\u003cli\u003eNo programs outside oncology\u003c\/li\u003e\n\u003cli\u003eHigher sensitivity to oncology approval timelines and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead-dependent oncology biotech faces steep burn, dilution and approval risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy dependence on Gilead (≈60% collaborative funding in 2024) creates cash-runway and governance risk; clinical-stage status means zero product revenue as of Dec 31, 2025. High R\u0026amp;D burn ($173.6M FY2024; $290M burn 2024–2025) and Q3 2025 net loss ($58.2M) raise dilution risk. Pipeline concentrated 100% in oncology; combination trials drive 2–3x costs and 20–30% lower approval odds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead funding share (2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 R\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$173.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash burn 2024–2025\u003c\/td\u003e\n\u003ctd\u003e$290M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 net loss\u003c\/td\u003e\n\u003ctd\u003e$58.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline concentration (2025)\u003c\/td\u003e\n\u003ctd\u003e100% oncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eArcus Biosciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Arcus Biosciences SWOT report you'll get, and the complete, editable version becomes available after checkout. You’re viewing a live preview of the real file: buy now to unlock the entire, detailed analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752502735225,"sku":"arcusbio-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/arcusbio-swot-analysis.png?v=1772241777","url":"https:\/\/growthsharematrix.com\/products\/arcusbio-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}